Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia
- 21 March 2013
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 121 (12) , 2199-2212
Abstract
Recent molecular studies of fetal hemoglobin (HbF) regulation have reinvigorated the field and shown promise for the development of clinical HbF inducers to be used in patients with β-thalassemia and sickle cell disease. However, while numerous promising inducers of HbF have been studied in the past in β-thalassemia patient populations, with limited success in some cases, no universally effective agents have been found. Here we examine the clinical studies of such inducers in an attempt to systematically review the field. We examine trials of agents, including 5-azacytidine, hydroxyurea, and short-chain fatty acids. This review highlights the heterogeneity of clinical studies done on these agents, including both the patient populations examined and the study end points. By examining the published studies of these agents, we hope to provide a resource that will be valuable for the design of future studies of HbF inducers in β-thalassemia patient populations.Keywords
This publication has 128 references indexed in Scilit:
- Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?Current Opinion in Hematology, 2011
- MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13Proceedings of the National Academy of Sciences, 2011
- KLF1 regulates BCL11A expression and γ- to β-globin gene switchingNature Genetics, 2010
- Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobinNature Genetics, 2010
- Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell diseaseProceedings of the National Academy of Sciences, 2010
- Paraspinal extramedullary hematopoiesis in patients with thalassemia intermediaEuropean Spine Journal, 2010
- Differences in response to fetal hemoglobin induction therapy in β-thalassemia and sickle cell diseaseBlood Cells, Molecules, and Diseases, 2009
- Hydroxycarbamide-induced changes in E/beta thalassemia red blood cellsAmerican Journal of Hematology, 2008
- Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemiaProceedings of the National Academy of Sciences, 2008
- Age-related changes in adaptation to severe anemia in childhood in developing countriesProceedings of the National Academy of Sciences, 2007